A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


South Korea, US Discuss Chip Investments Amid Tariff Plans
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
Trump Seeks Europe Repayment for U.S. Ukraine Military Aid
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal
Trump Peace Envoys Meet Zelenskiy in Kyiv After Putin Talks
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
U.S. Issues Cuba Health Alert as Illnesses Rise
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
China vs. NASA: The New Moon Race and What's at Stake by 2030
Tabletop particle accelerator could transform medicine and materials science
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 



